H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics to $8 from $9 and keeps a Buy rating on the shares post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Securing Success: The Crucial Role of IP Rights in Carisma Therapeutics’ Market Dominance
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics presents data for macrophages in liver fibrosis
- Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
- Carisma Therapeutics initiated with a Buy at BTIG